KR20050114214A - 백내장 및 녹내장을 진단 및 치료하기 위한 sgk 유전자패밀리의 용도 - Google Patents

백내장 및 녹내장을 진단 및 치료하기 위한 sgk 유전자패밀리의 용도 Download PDF

Info

Publication number
KR20050114214A
KR20050114214A KR1020057014582A KR20057014582A KR20050114214A KR 20050114214 A KR20050114214 A KR 20050114214A KR 1020057014582 A KR1020057014582 A KR 1020057014582A KR 20057014582 A KR20057014582 A KR 20057014582A KR 20050114214 A KR20050114214 A KR 20050114214A
Authority
KR
South Korea
Prior art keywords
hsgk1
gene
hsgk3
glaucoma
cataracts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020057014582A
Other languages
English (en)
Korean (ko)
Inventor
플로리안 랑
안드레아스 부스얀
Original Assignee
플로리안 랑
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 플로리안 랑 filed Critical 플로리안 랑
Publication of KR20050114214A publication Critical patent/KR20050114214A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/166—Cataract
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/168—Glaucoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020057014582A 2003-02-07 2004-02-05 백내장 및 녹내장을 진단 및 치료하기 위한 sgk 유전자패밀리의 용도 Withdrawn KR20050114214A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10305212A DE10305212A1 (de) 2003-02-07 2003-02-07 Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom
DE10305212.7 2003-02-07

Publications (1)

Publication Number Publication Date
KR20050114214A true KR20050114214A (ko) 2005-12-05

Family

ID=32730900

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057014582A Withdrawn KR20050114214A (ko) 2003-02-07 2004-02-05 백내장 및 녹내장을 진단 및 치료하기 위한 sgk 유전자패밀리의 용도

Country Status (13)

Country Link
EP (1) EP1663246A2 (cg-RX-API-DMAC7.html)
JP (1) JP2006519189A (cg-RX-API-DMAC7.html)
KR (1) KR20050114214A (cg-RX-API-DMAC7.html)
CN (1) CN1771039A (cg-RX-API-DMAC7.html)
AU (1) AU2004210416A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0407300A (cg-RX-API-DMAC7.html)
CA (1) CA2514703A1 (cg-RX-API-DMAC7.html)
DE (1) DE10305212A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05008394A (cg-RX-API-DMAC7.html)
PL (1) PL378399A1 (cg-RX-API-DMAC7.html)
RU (1) RU2005127808A (cg-RX-API-DMAC7.html)
WO (1) WO2004069258A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200506280B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102357260B1 (ko) * 2020-12-10 2022-02-08 주식회사 레피겐엠디 마이크로rna를 이용한 당뇨병성 신경병증의 예측 및 진단 방법 및 이를 위한 키트

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070191326A1 (en) * 2004-03-11 2007-08-16 Florian Lang Methods for modulating glutamate receptors for treating neuropsychiatric disorders comprising the use of modulators of serum and glucocorticoid inducible kinases
US20070203085A1 (en) * 2004-03-11 2007-08-30 Florian Lang Methods For Interfering With Fibrosis
DE102004059781A1 (de) * 2004-12-10 2006-06-22 Sanofi-Aventis Deutschland Gmbh Verwendung der Serum-/Glucocorticoid regulierten Kinase
US20060293378A1 (en) * 2005-06-28 2006-12-28 Mcintire Gregory Method of lowering intraocular pressure
WO2007037560A1 (ja) * 2005-09-30 2007-04-05 Link Genomics, Inc. Sgk2遺伝子の治療的又は診断的用途
AU2006318550A1 (en) * 2005-11-22 2007-05-31 Mcgill University Intraocular pressure-regulated early genes and uses thereof
WO2008079980A1 (en) * 2006-12-22 2008-07-03 Alcon Research, Ltd. Inhibitors of protein kinase c-delta for the treatment of glaucoma
DE102008029072A1 (de) * 2008-06-10 2009-12-17 Lang, Florian, Prof. Dr.med. Sgk3 als therapeutisches und diagnostisches Target für Alterserkrankungen
EP2667885B1 (en) * 2011-01-25 2018-08-08 Monell Chemical Senses Center Compositions and methods for providing or modulating sweet taste and methods of screening therefor
CN119303113A (zh) * 2024-09-03 2025-01-14 河北大学附属医院 Nedd4l基因在制备治疗血管内皮细胞增生性相关疾病药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69535673D1 (de) * 1994-08-30 2008-02-07 Univ Dundee Mittel zur induktion von apoptosis und zur therapieanwendung
CA2222562A1 (en) * 1995-06-07 1996-12-19 Jeffrey N. Miner Method for screening for receptor agonists and antagonists
US5925523A (en) * 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
DE19708173A1 (de) * 1997-02-28 1998-09-03 Dade Behring Marburg Gmbh Zellvolumenregulierte humane Kinase h-sgk
AU3991499A (en) * 1998-05-15 1999-12-06 Joslin Diabetes Center Independent regulation of basal and insulin-stimulated glucose transport
WO2000035946A1 (en) * 1998-12-14 2000-06-22 The University Of Dundee Methods
US6399655B1 (en) * 1998-12-22 2002-06-04 Johns Hopkins University, School Of Medicine Method for the prophylactic treatment of cataracts
DE19917990A1 (de) * 1999-04-20 2000-11-02 Florian Lang Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk
AU5840300A (en) * 1999-07-14 2001-01-30 University Of Lausanne Glutx polypeptide family and nucleic acids encoding same
US6416759B1 (en) * 1999-09-30 2002-07-09 The Regents Of The University Of California Antiproliferative Sgk reagents and methods
US20030236246A1 (en) * 2002-04-30 2003-12-25 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
DE10225844A1 (de) * 2002-06-04 2003-12-18 Lang Florian sgk und nedd als diagnostische und therapeutische targets

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102357260B1 (ko) * 2020-12-10 2022-02-08 주식회사 레피겐엠디 마이크로rna를 이용한 당뇨병성 신경병증의 예측 및 진단 방법 및 이를 위한 키트
WO2022124564A1 (ko) * 2020-12-10 2022-06-16 주식회사 레피겐엠디 마이크로rna를 이용한 당뇨병성 신경병증의 예측 및 진단 방법 및 이를 위한 키트

Also Published As

Publication number Publication date
CA2514703A1 (en) 2004-08-19
ZA200506280B (en) 2006-05-31
WO2004069258A3 (de) 2005-02-24
RU2005127808A (ru) 2006-05-27
PL378399A1 (pl) 2006-04-03
WO2004069258A2 (de) 2004-08-19
DE10305212A1 (de) 2004-08-19
AU2004210416A1 (en) 2004-08-19
CN1771039A (zh) 2006-05-10
MXPA05008394A (es) 2005-10-05
BRPI0407300A (pt) 2006-02-07
EP1663246A2 (de) 2006-06-07
JP2006519189A (ja) 2006-08-24

Similar Documents

Publication Publication Date Title
Roy et al. Fibronectin overexpression in retinal microvessels of patients with diabetes.
US7867492B2 (en) Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies
JP2006514021A (ja) Janusチロシンキナーゼ3(Jak3)を選択的に阻害するための方法
Wang et al. Increased expression of serum amyloid A in glaucoma and its effect on intraocular pressure
JP2006519189A (ja) 白内障および緑内障を診断および治療するための、sgk遺伝子ファミリーの使用
US20090029904A1 (en) Compositions and methods for treatment of insulin-resistance diseases
WO2021173712A1 (en) Molecular biomarkers and targets for fuchs' endothelial corneal dystrophy and glaucoma
CN100406570C (zh) 用作诊断和治疗靶标的Sgk和Nedd
CN1193756C (zh) 用作诊断和治疗靶点的sgk2和sgk3
JP2004507262A (ja) 慢性炎症性気道疾病の炎症状態に明瞭な影響を与える物質の同定方法
JP2019182873A (ja) 膵臓炎、腎損傷および腎臓癌を治療および予防するための組成物および方法
JP4762552B2 (ja) 診断用および治療用標的としてのsgk1
Li et al. Estrogen receptor 1 activation suppresses microglia-derived Tnf-α signaling as a photoreceptor self-protection mechanism
US20130040298A1 (en) Two-pore channels as regulators of proliferation in cancer
JP2004516038A (ja) 慢性炎症性気道疾患の炎症性状態に陽性の影響を与える物質を同定するための方法
US8372582B2 (en) Methods of modulating metabolic memory
US20040092475A1 (en) Organic compounds
US20020160438A1 (en) Method for identifying compounds which positively influence inflammatory conditions
KR20050016494A (ko) 진단 및 치료 표적으로 사용되는 sgk 및 nedd
US20030068660A1 (en) Methods of ameliorating arthritis by modulating JNK signalsome activity
WO2008016118A1 (en) Agent targeting dopamine receptor and screening method therefor
AU2007211655A1 (en) Methods for interfering with glucocorticoid induced gastric acid secretion
CN101506234A (zh) Gprc变异体在帕金森氏病治疗和诊断中的鉴定和使用
HK1061801B (en) Sgk2 and sgk3 used as diagnostic and therapeutic targets

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050808

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid